Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have earned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.50.

A number of brokerages have recently commented on SYN. ValuEngine raised Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research raised Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, August 9th.

Synthetic Biologics (NYSEMKT SYN) opened at 0.8751 on Wednesday. Synthetic Biologics has a 52 week low of $0.41 and a 52 week high of $1.63. The firm has a 50-day moving average of $0.86 and a 200 day moving average of $0.64. The firm’s market capitalization is $112.23 million.

Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Analysts predict that Synthetic Biologics will post ($0.17) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/18/synthetic-biologics-inc-syn-given-average-rating-of-hold-by-analysts.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its position in Synthetic Biologics by 8,102.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock worth $639,000 after acquiring an additional 1,115,343 shares during the period. LMR Partners LLP acquired a new stake in Synthetic Biologics during the 2nd quarter worth about $194,000. Bank of New York Mellon Corp boosted its position in Synthetic Biologics by 3.1% during the 1st quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after acquiring an additional 7,962 shares during the period. UBS Group AG boosted its position in Synthetic Biologics by 10.3% during the 1st quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after acquiring an additional 20,038 shares during the period. Finally, Susquehanna International Group LLP boosted its position in Synthetic Biologics by 76.4% during the 2nd quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock worth $107,000 after acquiring an additional 82,030 shares during the period.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.